Novartis' Coartem Baby wins approval in 16 countries
NVS•Novartis said Coartem Baby, its malaria treatment for newborns and young infants, has been approved in 16 countries. Its next-generation antimalarial KLU156 received priority review and was submitted to Swissmedic and the U.S. FDA.
1. Approvals and review
Novartis said Coartem Baby, a malaria treatment for newborns and young infants, has secured approval in 16 countries. The company also said its next-generation antimalarial KLU156 (ganaplacide/lumefantrine) received priority review and was submitted to Swissmedic and the U.S. FDA.
